Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for Period Ending September 2023 and Year Ending March 2024
August 09, 2023 at 12:00 am EDT
Share
Sawai Group Holdings Co., Ltd. provided consolidated earnings guidance for period ending September 2023 and year ending March 2024. For period ending September 2024, the company expects the Sales of JPY 105,700 million. Operating profit of JPY 7,000 million. Profit attributable to owners of parent of JPY 5,100 million. Basic earnings per share of JPY 116.43.
For the year ending March 2024, the company expects the Sales of JPY 217,200 million. Operating profit of JPY 15,100 million. Profit attributable to owners of parent of JPY 11,300 million. Basic earnings per share of JPY 257.97.
Sawai Group Holdings Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of medical and over-the-counter drugs. The Company operates in two segments. The Japan segment is engaged in medical and healthcare-related businesses such as manufacture and sale of pharmaceuticals and medical devices, as well as various related businesses. The America segment is engaged in the sale of manufactured pharmaceutical products to wholesale stores in America. The company is also engaged in the research and development of pharmaceutical products.